Omega-3 fatty acids in contrast to omega-6 protect against pneumococcal pneumonia

Microb Pathog. 2020 Apr:141:103979. doi: 10.1016/j.micpath.2020.103979. Epub 2020 Jan 16.

Abstract

Purpose: The aim of this study was to assess if long-term supplementation of omega-3 fatty acids or a diet rich in omega-6 fatty acids ameliorates disease severity in a murine model of pneumococcal pneumonia. We hypothesize that long-term dietary supplementation of omega-3 fatty acids will reduce inflammation, disease severity and improve survival compared to omega-6 fatty acids.

Methods: Mice receiving diets supplemented with Omega-3 or Omega-6 for two months were intranasally infected with Streptococcus pneumoniae. We analyzed survival, bacterial burden, histopathology and inflammatory biomarkers.

Results: Our results showed that Omega-3 supplementation had increased survival (p = 0.005), less bacteremia (p = 0.0001) and lower bacterial burden in the lungs (p = 0.0002) when compared to the Omega-6 supplementation. Overall, Omega-3 reduced lung pathology, in particular peribronchial inflammation and cell death. Analyses of lung homogenates showed the Omega-3 cohort had decreased levels of the inflammatory cytokine interleukin-6 and an increase in anti-inflammatory cytokine interleukin-10.

Conclusions: Supplementation of mouse diets with Omega-3 fatty acids improved survival, bacterial invasion in the blood and lungs as well as decreased overall lung tissue inflammation and cell death when compared to the Omega-6 supplemented diets. Translation of these findings in humans may improve outcomes of patients at risk for pneumonia.

Keywords: Fatty acids; Inflammation; Omega-3; Omega-6; Pneumonia; Streptococcus pneumoniae.

MeSH terms

  • Animal Feed
  • Animals
  • Anti-Inflammatory Agents / administration & dosage*
  • Bacterial Load
  • Dietary Supplements
  • Disease Models, Animal
  • Disease Susceptibility
  • Fatty Acids, Omega-3 / administration & dosage*
  • Fatty Acids, Omega-6 / administration & dosage*
  • Lung / drug effects
  • Lung / microbiology
  • Lung / pathology
  • Mice
  • Mortality
  • Pneumonia, Pneumococcal / drug therapy
  • Pneumonia, Pneumococcal / microbiology*
  • Pneumonia, Pneumococcal / mortality
  • Pneumonia, Pneumococcal / pathology
  • Streptococcus pneumoniae / drug effects*
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Fatty Acids, Omega-3
  • Fatty Acids, Omega-6